Skip to main content
  • Our Mission
  • About Us
  • Founders
  • Investors
  • Careers
Copyright © 2023 Kisbee Therapeutics, LLC. All Rights Reserved.

Redefining the treatment of neurodegenerative disease

moving 3d dark liquid material

Our Mission

Changing the paradigm of treating neurodegenerative disease

Our mission is to translate unique genetic and biochemical insights regarding lipid biology into therapies that promote brain health and repair. We believe our novel technology platform and approach will unlock new opportunities to address significant unmet need across a range of acute and chronic conditions, including Traumatic Brain Injury, Stroke, Multiple Sclerosis, and Alzheimer’s Disease.

Our Mission

About Us

Great teams are required to achieve great success

We are a growing team of scientists and entrepreneurs dedicated to advancing our technology in service of patients and their loved ones. With a diverse culture of experience and perspective, we strive to support and challenge one another, fostering an environment of care, respect, and collaboration. New ideas and innovation fuel us. Science and data guide us. Novel challenges and opportunities bring out our best. Passionate and driven, we aspire to overcome obstacles with creativity and careful risk-taking, knowing that we are making a difference in the lives of patients.

At Kisbee, we believe that great teams are built on a foundation of kindness, honesty, and balance. We work hard, but recognize that we all have lives outside the lab and office. We celebrate our successes as much as our failures, knowing that both are stepping stones on the journey to changing the way we approach brain health. Together, we will redefine the way we treat neurodegenerative disease.

We Value

  • Inherent trust
  • Unabashed curiosity
  • Fearless pursuit
  • Unconditional respect
  • Thoughtful transparency
About Us

Founders

Meet the experts behind our vision

  • Banjamin Cravatt headshot
    Benjamin Cravatt, PhD
  • Emily Ricq headshot
    Emily Ricq, PhD
  • Jennifer Lippincott-Schwartz headshot
    Jennifer Lippincott-Schwartz, PhD
  • Stuart Schreiber headshot
    Stuart Schreiber, PhD
Founders

Investors

Arch Venture Partners
Newpath Partners
Investors

Join us in our journey to revolutionize the treatment of neurodegenerative disease

Kisbee is an exciting fast-growing company with tremendous career growth opportunity. We are actively hiring across a range of roles in R&D, HR, Finance, and Operations. To inquire about open roles, please email recruiting@kisbeetx.com

Join Us
Careers
Banjamin Cravatt headshot

Benjamin Cravatt, PhD

Benjamin F. Cravatt, Ph.D., is a the Gilula Chair of Chemical Biology and Professor in the Department of Chemistry at The Scripps Research Institute. His research group develops and applies chemical proteomic technologies for protein and drug discovery on a global scale and has particular interest in studying biochemical pathways in the nervous system and cancer. Dr. Cravatt is a co-founder of Activx Biosciences (acquired by Kyorin Pharmaceuticals), Abide Therapeutics (acquired by Lundbeck Pharmaceuticals), and Vividion Therapeutics. His honors include a Searle Scholar Award, the Eli Lilly Award in Biological Chemistry, a Cope Scholar Award, the ASBMB Merck Award, the Royal Society of Chemistry Jeremy Knowles Award, and memberships in the National Academy of Sciences, National Academy of Medicine, and American Academy of Arts and Sciences.

Dr. Cravatt obtained his undergraduate education at Stanford University, receiving a B.S. in the Biological Sciences and a B.A. in History. He then received a Ph.D. from The Scripps Research Institute (TSRI) in 1996, and joined the faculty at TSRI in 1997.

Copyright © 2023 Kisbee Therapeutics, Inc. All Rights Reserved.
Redefining the treatment of neurodegenerative disease
  • Our Mission
  • About Us
  • Founders
  • Investors
  • Careers